Login to Your Account

$975M Total Plus Profit Split

Pharmacyclics Gets $150M Up Front from J&J for Btk Inhibitor

By Trista Morrison
Staff Writer

Monday, December 12, 2011

Hematologic cancers always grab the spotlight at the American Society of Hematology (ASH) annual meeting, which kicked off this weekend, but Pharmacyclics Inc. got a head start last week by announcing a $975 million deal with Janssen Biotech Inc. for Phase II hematologic cancer drug PCI-32765.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription